Clinical trial
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
NCT00291785 · CTI BioPharma, Industry · Completed
Key facts
| NCT number | NCT00291785 |
|---|---|
| Title | Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer |
| Official title | Phase I/II Study of CT-2106 in Combination With Infusional 5-fluorouracil/Folinic Acid (5-FU/FA)(de Gramont Schedule) as Second Line in Patients With Metastatic Colorectal Cancer Failing an Oxaliplatin Plus 5-FU/FA Regimen |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | CT-2106, Folinic acid, 5-FU (fluorouracil) |
| Enrollment | 48 |
| Start date | Jan 1, 2004 |
| Primary completion | Aug 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Feb 15, 2006 |
| Last update posted | Jun 8, 2011 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: